Accuray (ARAY) stock plunges 27% after Q3 FY2026 earnings miss, weaker sales, higher costs and withdrawn guidance.

Accuray Incorporated ARAY is well-poised for growth in the coming quarters, courtesy of continued robust demand for its products. The optimism, led by robust global performance in the third quarter of ...

Q3 FY2026 earnings call recap: revenue miss, guidance withdrawn amid Middle East delays & China tariffs, plus cost cuts & backlog—read now.

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks ...

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

Fintel reports that on May 7, 2026, BTIG downgraded their outlook for Accuray (NasdaqGS:ARAY) from Buy to Neutral. Analyst ...

Accuray Incorporated ARAY recently announced that new data presented at the 2024 Radiosurgery Society (RSS) Meeting in Chicago supports the use of the CyberKnife System in the treatment of high-risk ...

ARAY is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of ARAY shares has increased $0.09 since the market last closed. This is a 29.65% ...

Accuray Incorporated ARAY recently received approval from the Japanese Ministry of Health, Labor and Welfare (Shonin) with respect to marketing the CyberKnife Robotic Radiosurgery System in Japan.